In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates, and Siegfried Schmitt, Parexel, give their opinions on why those working in the pharmaceutical industry should lend their voices to draft regulations.

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

Recent developments show how innovations and treatments for cancer are rapidly advancing.

Major pharmaceutical investments in the United States are expanding API, capsule, and packaging capacity, enhancing supply chain resilience and supporting domestic drug production.

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

In episode 27, Christopher Hopkins, PhD; Omkar Kawalekar, PhD; Barnaby Pickering; and Jerry Rosenbaum, MD, go behind the headlines.

Spotlighting global biopharma innovation, the event will unite leaders to discuss digitalization, sustainable manufacturing, and future-ready development.

The first needle-free adrenaline treatment launches in the UK, validating non-invasive delivery with real-world data comparable to injection effectiveness.

Take this quiz to test your comprehension of one of our recent feature articles.

As the conference approaches, scientists are reviewing new technologies that enhance manufacturing process control, product integrity, and regulatory compliance through automation and sustainable materials.

Biopharma R&D strategy pivots: M&A favors late-stage assets, obesity deals surge, AI accelerates manufacturing, and policy drives strategic US facility investment.

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.

Advanced biotech equipment, driven by R&D investment and personalized medicine, is essential for scalable drug production and development into the next decade, according to a BCC Research report.

This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development or orphan drugs.

Biopharma data showed M&A strength, selective venture capital favoring Phase II, record obesity deals, and significant upfronts flowing toward innovation in China were key in Q3 2025.